Page 5 - ரென்ஜி இஷீபாஷி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ரென்ஜி இஷீபாஷி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ரென்ஜி இஷீபாஷி Today - Breaking & Trending Today

Chronic disease root of young man's abnormally gray hair and facial changes

Chronic disease root of young man s abnormally gray hair and facial changes
  18:03 UTC+8, 2021-05-07
  0
A chronic, progressive disease was discovered to be the reason why a man in his 20s experienced a sudden increase of gray hair and facial changes.
  18:03 UTC+8, 2021-05-07
  0
A chronic, progressive disease was discovered to be the reason why a man in his 20s experienced a sudden increase of gray hair and facial changes, local doctors said.
The man recently went to Renji Hospital to find out why the changes had taken place.
Doctors suspected he suffered from acromegaly, a chronic disease characterized by enlargement of head bones, soft parts of the feet and hands and sometimes other parts of the body due to excessive secretion of growth hormones by the pituitary gland. ....

Ma Jing , Renji Hospital , மா ஜிங் , ரென்ஜி மருத்துவமனை ,

China science, technology news summary -- May 5

China science, technology news summary May 5
Xinhua
06 May 2021, 02:05 GMT+10
BEIJING, May 5 (Xinhua) The following is a summary of published science and technology news of China.
IMMUNE THERAPY INSTITUTE
Shanghai has established an immune therapy institute to promote China s innovation and competitiveness in immunological disease prevention and control.
Established at the Renji Hospital under the Shanghai Jiao Tong University School of Medicine, the institute will focus on three research areas: tumor immunotherapy, chronic inflammatory diseases and transplantation immunology, and infectious diseases and vaccines.
MISSION TO EDGE OF SOLAR SYSTEM
Chinese scientists are evaluating the feasibility of a project to send spacecraft to the edge of the solar system, said Wu Weiren, chief designer of China s lunar exploration program. ....

Wu Weiren , Shanghai Jiao Tong University School Of Medicine , Renji Hospital , Shanghai Jiao Tong University School , ஷாங்காய் ஜியாவோ நாக்கு பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து , ரென்ஜி மருத்துவமனை , ஷாங்காய் ஜியாவோ நாக்கு பல்கலைக்கழகம் பள்ளி ,

China science, technology news summary -- May 5 - Buz & Tech News

China science, technology news summary -- May 5 - Buz & Tech News
sina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com Daily Mail and Mail on Sunday newspapers.

Wu Weiren , Shanghai Jiao Tong University School Of Medicine , Renji Hospital , Shanghai Jiao Tong University School , ஷாங்காய் ஜியாவோ நாக்கு பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து , ரென்ஜி மருத்துவமனை , ஷாங்காய் ஜியாவோ நாக்கு பல்கலைக்கழகம் பள்ளி ,

Across China: Shanghai establishes immune therapy institute to bring advances from lab to clinic - Buz & Tech News

2021-05-05 08:35:20 GMT2021-05-05 16:35:20(Beijing Time) Xinhua English
SHANGHAI, May 5 (Xinhua) Shanghai has accelerated its pace of immunological research to take the lead in boosting China s innovation in the prevention and treatment of immunological diseases.
The newly launched Shanghai Immune Therapy Institute is the latest example of the city s efforts to build world-class immunology research hubs. Established at the Renji Hospital under the Shanghai Jiao Tong University School of Medicine, the institute will focus on three research areas: tumor immunotherapy, chronic inflammatory diseases and transplantation immunology, and infectious diseases and vaccines.
The institute aims to become a frontier research and development center with global talent by 2025, and one of the world s leading institutes in the fields of new drug targets, new mechanisms, antibody-drug development, immunotherapy and other major immune-related diseases by 2035, according to a hos ....

Dong Chen , Shanghai Jiao Tong University School Of Medicine , School Of Medicine , Shanghai Immune Therapy Institute , Chinese Academy Of Sciences , Renji Hospital , Shanghai Jiao Tong University School , Fan Xianqun , Chinese Academy , டாங் சென் , ஷாங்காய் ஜியாவோ நாக்கு பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து , பள்ளி ஆஃப் மருந்து , சீன கலைக்கழகம் ஆஃப் அறிவியல் , ரென்ஜி மருத்துவமனை , ஷாங்காய் ஜியாவோ நாக்கு பல்கலைக்கழகம் பள்ளி , சீன கலைக்கழகம் ,

NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Published: Apr 12, 2021
SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This is the third approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) afte ....

United States , San Francisco , Huang Yiran , Patricia Keegan , Junshi Biosciences , Guo Jun , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Shanghai Jiao Tong University School Of Medicine , Guidelines Of Chinese Society Clinical Oncology , Ir Team , University Cancer Hospital , Drug Administration , National Reimbursement Drug List , National Medical Products Administration , Pr Team , Chief Medical Officer , Professor Guo Jun , Peking University Cancer Hospital , Professor Huang Yiran , Renji Hospital , Shanghai Jiao Tong University School , Independent Review Committee , Chinese Society , Clinical Oncology , Breakthrough Therapy Designation ,